Physician profile
Charles S Markle
NPI 1194774927
$211,509.50
in general payments reported to CMS, 2019-2025
71 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $29K · 2021: $39K · 2022: $35K · 2023: $33K · 2024: $19K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Food and Beverage: $16K · Travel and Lodging: $841 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,414.25 |
| Food and Beverage | $15,509.59 |
| Travel and Lodging | $841.45 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56,416.00 | 2020-2025 | |
| Lilly USA, LLC | $47,400.36 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Emd Serono, INC. | $46,887.83 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $20,530.65 | 2019-2025 | Austedo Xr, Austedo Xr |
| Genzyme Corporation | $9,442.12 | 2019-2025 | |
| Allergan, INC. | $8,303.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $2,722.05 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $2,711.48 | 2019-2023 | Oxtellar Xr |
| Lundbeck LLC | $1,403.76 | 2020-2025 | Vyepti, Rexulti |
| Celgene Corporation | $1,317.28 | 2021-2025 | Zeposia |
| Ucb, INC. | $1,262.62 | 2019-2025 | Zilbrysq, Briviact, Rystiggo |
| Biogen, INC. | $1,133.52 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Sk Life Science, INC. | $1,090.72 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $990.58 | 2019-2025 | Nuplazid |
| Eisai INC. | $839.16 | 2019-2025 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Markle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.